JANE ROSE REPORTING

rose

800-825-3341

74 FIFTH AVENUE NYC 10011
JANE ROSE REPORTING.COM
JANE ROSE @ JANE ROSE REPORTING.COM

US District Court - New Jersey

Jazz Pharmaceuticals

v.

Roxane Laboratories

[redacted]

Video Deposition of:

Glenn Van Buskirk, Ph.D.

October 28, 2015

[redacted]

GLENN A. VAN BUSKIRK, Ph.D., Nonclinical Drug Development Consulting Services, LLC, having been duly sworn, was examined and testified as follows:

[redacted]

[redacted]

Q. You didn't attend any advisory committee meetings for -- for GHB or Xyrem in front of the FDA, did you?

A. No, I did not.

Q. And you were not aware of any 2001 advisory committee meetings before the FDA, correct?

A. No. Until you mentioned advisory meetings, I didn't even know there were such things. Oh, I know they exist; I didn't know they existed for this compound. So, no, I was not aware of it.

Q. Something I forgot to get in. Your educational background, you have a Bachelor of Science in pharmacy, correct?

A. I do.

Q. And a master's in pharmaceutical science?

A. Correct.

Q. And a Ph.D. in pharmaceutical science, correct?

A. That is also correct.

Q. And you -- you are also a licensed pharmacist?

A. Yes, I am.

[redacted]

[redacted]

Q. Okay. Do you monitor the Federal Register for notices of advisory committee meetings for unapproved drugs?

A. No, that's not something I do.

Q. Do individuals with degrees in pharmacy generally monitor the Federal Register for notices on unapproved drugs?

A. Not unless they're in regulatory affairs. And from my perspective as a scientist, we monitor it for the general regulations around such things as good manufacturing practices and specifications and things that affect our daily lives. Other people monitor the regulatory component.

[redacted]